Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study

G. Bolis, G. Bortolozzi, G. Carinelli, M. D'Incalci, F. Gramellini, L. Morasca, C. Mangioni

Research output: Contribution to journalArticlepeer-review

Abstract

After intensive staging 74 ovarian cancer patients were randomized to two arms balanced for stage and post-surgery residual tumor. The two regimens were CTX 100 mg/day continuously and ADM 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day. The response rates were respectively 42% and 52%. Median survival times were 13 and 14 months. The incidence of side effects was significantly higher in the combination-treatment arm. No other statistical differences were found.

Original languageEnglish
Pages (from-to)129-132
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume4
Issue number2
DOIs
Publication statusPublished - 1980

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology

Fingerprint Dive into the research topics of 'Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer - A Randomized Clinical Study'. Together they form a unique fingerprint.

Cite this